+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

In vitro activities of quinupristin-dalfopristin and cefepime, alone and in combination with various antimicrobials, against multidrug-resistant staphylococci and enterococci in an in vitro pharmacodynamic model



In vitro activities of quinupristin-dalfopristin and cefepime, alone and in combination with various antimicrobials, against multidrug-resistant staphylococci and enterococci in an in vitro pharmacodynamic model



Antimicrobial Agents and ChemoTherapy 46(8): 2606-2612



Use of combinations of antimicrobials that together achieve synergistic activities against targeted microorganisms is one potential strategy for overcoming bacterial resistance. As the incidence of infections caused by multidrug-resistant staphylococci and enterococci increases, the importance of devising additional synergistic drug combinations for these bacteria is magnified. We evaluated a number of antimicrobial combinations, with a focus on quinupristin-dalfopristin (Q-D), cefepime, and linezolid, using a previously described in vitro pharmacodynamic model. The combination of Q-D with either linezolid or vancomycin, as well as the combination of cefepime-vancomycin, resulted in enhanced killing (> or =2-log(10) increase in killing versus the most-active single agent) against methicillin-resistant Staphylococcus aureus (MRSA) 494. An improved effect (<2 log(10) kill increase in kill) against MRSA 494 was noted for cefepime plus either Q-D or linezolid, as well as linezolid-vancomycin. Similar relationships were observed for a methicillin-susceptible S. aureus isolate (isolate 1199). Against methicillin-resistant S. epidermidis R444, enhanced killing was achieved with the combination of cefepime-linezolid, while improvement was noted for vancomycin with either cefepime or linezolid. The combination of cefepime and vancomycin also achieved enhanced killing against a glycopeptide-intermediate-susceptible S. aureus isolate (isolate 992). The combination of linezolid and doxycycline achieved an enhanced effect against vancomycin-resistant Enterococcus faecalis (VREFc) and E. faecium. Q-D plus ampicillin or linezolid resulted in similar enhancement of activity against the VREFc isolate. The results of this study suggest a number of novel antimicrobial combinations that may be useful against staphylococci and enterococci. Combination regimens including cefepime, Q-D, and/or linezolid warrant further investigation for the treatment of refractive infections due to multidrug-resistant gram-positive pathogens.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 010811581

Download citation: RISBibTeXText

PMID: 12121940

DOI: 10.1128/aac.46.8.2606-2612.2002


Related references

Evaluation of the in vitro activities of quinupristin-dalfopristin , cefepime , linezolid , ampicillin , doxocycline , and vancomycin , alone and/or in combination against vancomycin-resistant Enterococcus faecalis and E faecium , methicillin-resistant Staphylococcus aureus , and glycopeptide intermediate-susceptible S aureus in an in vitro pharmacodynamic infection model IVPM. Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy 40: 183, 2000

In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against Staphylococci and Enterococci, including vancomycin- intermediate and -resistant strains. Antimicrobial Agents and ChemoTherapy 44(4): 1062-1066, 2000

In vitro activities of Daptomycin, Linezolid, and Quinupristin-Dalfopristin against a challenge panel of Staphylococci and Enterococci, including vancomycin-intermediate staphylococcus aureus and vancomycin-resistant Enterococcus faecium. Microbial Drug Resistance 9(4): 389-393, 2003

Bactericidal activities of daptomycin, quinupristin-dalfopristin, and linezolid against vancomycin-resistant Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrobial Agents and ChemoTherapy 47(12): 3960-3963, 2003

Pharmacodynamics of cefepime alone and in combination with various antimicrobials against methicillin-resistant Staphylococcus aureus in an in vitro pharmacodynamic infection model. Antimicrobial Agents and ChemoTherapy 49(1): 302-308, 2004

Treatment of Vancomycin-Resistant Enterococcus faecium with Rp 59500 (Quinupristin-Dalfopristin) Administered by Intermittent or Continuous Infusion, Alone or in Combination with Doxycycline, in an In Vitro Pharmacodynamic Infection Model with Simulated Endocardial Vegetations. Antimicrobial Agents and Chemotherapy 42(10): 2710-2717, 1998

Treatment of vancomycin-resistant Enterococcus faecium with RP 59500 (quinupristin-dalfopristin) administered by intermittent or continuous infusion, alone or in combination with doxycycline, in an in vitro pharmacodynamic infection model with simulated endocardial vegetations. Antimicrobial Agents and ChemoTherapy 42(10): 2710-2717, 1998

In vitro activity of chloramphenicol alone and in combination with vancomycin, ampicillin, or RP 59500 (Quinupristin/Dalfopristin) against vancomycin-resistant enterococci. Diagnostic Microbiology and Infectious Disease 29(3): 203-205, 1997

Activity of combination of quinupristin-dalfopristin and vancomycin in vitro and in experimental endocarditis due to Staphylococcus aureus susceptible or resistant to quinupristin. Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy 40: 57, 2000

Quinupristin-dalfopristin alone or in combination with Rifampin in vitro and in experimental endocarditis caused by Staphylococcus aureus harboring different phenotypes of resistance to quinupristin or dalfopristin. Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy 39: 63, 1999

Comparative in-vitro activities of moxifloxacin, trovafloxacin, quinupristin/dalfopristin and linezolid against staphylococci. Journal of Antimicrobial ChemoTherapy 43(4): 569-573, 1999

In vitro activity of RP 59500 (quinupristin/dalfopristin) against antibiotic-resistant strains of Streptococcus pneumoniae and enterococci. Diagnostic Microbiology and Infectious Disease 21(3): 169-173, 1995

Comparative in vitro activity of quinupristin/dalfopristin against multidrug resistant Enterococcus faecium. Diagnostic Microbiology and Infectious Disease 25(3): 127-131, 1996

In vitro activities of daptomycin, vancomycin, quinupristin- dalfopristin, linezolid, and five other antimicrobials against 307 gram-positive anaerobic and 31 Corynebacterium clinical isolates. Antimicrobial Agents and ChemoTherapy 47(1): 337-341, 2003

In Vitro Activities of Daptomycin, Vancomycin, Quinupristin- Dalfopristin, Linezolid, and Five Other Antimicrobials against 307 Gram-Positive Anaerobic and 31 Corynebacterium Clinical Isolates. Antimicrobial Agents and ChemoTherapy 47(4): 1486-1486, 2003